Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (351-360 of 379) with videos related to

Pageof 38
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 19, 2008
Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseasesMichael Hertl, Detlef Zillikens, Luca Borradori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Volker Diehl, et al.
Lancet (London, England)|May 5, 2009
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trialsJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
The Cochrane Database of Systematic Reviews|July 10, 2009
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient dataJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
Blood|May 3, 2014
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse eventMitul D Gandhi, Andrew M Evens, Timothy S Fenske, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphomaAnas Younes, Ajay K Gopal, Scott E Smith, et al.
The Lancet. Oncology|July 25, 2016
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trialAnas Younes, Armando Santoro, Margaret Shipp, et al.
British Journal of Haematology|May 11, 2022
Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysisJesko Momotow, Ina Bühnen, Karolin Trautmann-Grill, et al.
Blood Advances|August 2, 2023
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 studyStephen M Ansell, Paul J Bröckelmann, Gottfried von Keudell, et al.
Nature Communications|May 20, 2020
Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphomaLorenz Thurner, Sylvia Hartmann, Natalie Fadle, et al.
Pageof 38

Showing results (351-360 of 379) with videos related to

Sort By:
Pageof 38
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 19, 2008
Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseasesMichael Hertl, Detlef Zillikens, Luca Borradori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study GroupPeter Borchmann, Heinz Haverkamp, Volker Diehl, et al.
Lancet (London, England)|May 5, 2009
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trialsJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
The Cochrane Database of Systematic Reviews|July 10, 2009
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient dataJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
Blood|May 3, 2014
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse eventMitul D Gandhi, Andrew M Evens, Timothy S Fenske, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphomaAnas Younes, Ajay K Gopal, Scott E Smith, et al.
The Lancet. Oncology|July 25, 2016
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trialAnas Younes, Armando Santoro, Margaret Shipp, et al.
British Journal of Haematology|May 11, 2022
Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysisJesko Momotow, Ina Bühnen, Karolin Trautmann-Grill, et al.
Blood Advances|August 2, 2023
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 studyStephen M Ansell, Paul J Bröckelmann, Gottfried von Keudell, et al.
Nature Communications|May 20, 2020
Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphomaLorenz Thurner, Sylvia Hartmann, Natalie Fadle, et al.
Pageof 38